These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 22153342

  • 1. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
    Becknell NC, Dandu RR, Lyons JA, Aimone LD, Raddatz R, Hudkins RL.
    Bioorg Med Chem Lett; 2012 Jan 01; 22(1):186-9. PubMed ID: 22153342
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.
    Dandu RR, Lyons JA, Raddatz R, Huang Z, Aimone LD, Hudkins RL.
    Bioorg Med Chem Lett; 2012 Mar 15; 22(6):2151-3. PubMed ID: 22365751
    [Abstract] [Full Text] [Related]

  • 3. Identification of biaryl sulfone derivatives as antagonists of the histamine H₃ receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).
    Semple G, Santora VJ, Smith JM, Covel JA, Hayashi R, Gallardo C, Ibarra JB, Schultz JA, Park DM, Estrada SA, Hofilena BJ, Smith BM, Ren A, Suarez M, Frazer J, Edwards JE, Hart R, Hauser EK, Lorea J, Grottick AJ.
    Bioorg Med Chem Lett; 2012 Jan 01; 22(1):71-5. PubMed ID: 22172695
    [Abstract] [Full Text] [Related]

  • 4. Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists.
    Berlin M, Lee YJ, Boyce CW, Wang Y, Aslanian R, McCormick KD, Sorota S, Williams SM, West RE, Korfmacher W.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2359-64. PubMed ID: 20188550
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.
    Sasaki T, Takahashi T, Nagase T, Mizutani T, Ito S, Mitobe Y, Miyamoto Y, Kanesaka M, Yoshimoto R, Tanaka T, Takenaga N, Tokita S, Sato N.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4232-6. PubMed ID: 19520574
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, and structure-activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethyl spiropiperidine.
    Yoshizumi T, Miyazoe H, Ito H, Tsujita T, Takahashi H, Asai M, Ozaki S, Ohta H, Okamoto O.
    Bioorg Med Chem Lett; 2008 Jul 01; 18(13):3778-82. PubMed ID: 18515099
    [Abstract] [Full Text] [Related]

  • 7. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
    Santora VJ, Covel JA, Hayashi R, Hofilena BJ, Ibarra JB, Pulley MD, Weinhouse MI, Semple G, Ren A, Pereira G, Edwards JE, Suarez M, Frazer J, Thomsen W, Hauser E, Lorea J, Grottick AJ.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4133-6. PubMed ID: 18554904
    [Abstract] [Full Text] [Related]

  • 8. Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.
    Lau JF, Jeppesen CB, Rimvall K, Hohlweg R.
    Bioorg Med Chem Lett; 2006 Oct 15; 16(20):5303-8. PubMed ID: 16908150
    [Abstract] [Full Text] [Related]

  • 9. A new class of histamine H3 receptor antagonists derived from ligand based design.
    Roche O, Rodríguez Sarmiento RM.
    Bioorg Med Chem Lett; 2007 Jul 01; 17(13):3670-5. PubMed ID: 17498953
    [Abstract] [Full Text] [Related]

  • 10. Spiro-piperidine azetidinones as potent TRPV1 antagonists.
    Xiao D, Palani A, Aslanian R, McKittrick BA, McPhail AT, Correll CC, Phelps PT, Anthes JC, Rindgen D.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):783-7. PubMed ID: 19114307
    [Abstract] [Full Text] [Related]

  • 11. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
    Berglund S, Egner BJ, Gradén H, Gradén J, Morgan DG, Inghardt T, Giordanetto F.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4274-9. PubMed ID: 19500982
    [Abstract] [Full Text] [Related]

  • 12. Synthesis of spiro[chroman-2,4'-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitors.
    Shinde P, Srivastava SK, Odedara R, Tuli D, Munshi S, Patel J, Zambad SP, Sonawane R, Gupta RC, Chauthaiwale V, Dutt C.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):949-53. PubMed ID: 19097787
    [Abstract] [Full Text] [Related]

  • 13. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M, Kobayashi K, Ito H, Miyazoe H, Tsujino T, Nakama C, Kawamoto H, Ando M, Ito S, Suzuki T, Kanno T, Tanaka T, Tahara Y, Tani T, Tanaka S, Tokita S, Sato N.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4325-9. PubMed ID: 19487123
    [Abstract] [Full Text] [Related]

  • 14. 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists.
    Fletcher SR, Burkamp F, Blurton P, Cheng SK, Clarkson R, O'Connor D, Spinks D, Tudge M, van Niel MB, Patel S, Chapman K, Marwood R, Shepheard S, Bentley G, Cook GP, Bristow LJ, Castro JL, Hutson PH, MacLeod AM.
    J Med Chem; 2002 Jan 17; 45(2):492-503. PubMed ID: 11784153
    [Abstract] [Full Text] [Related]

  • 15. Acidic elements in histamine H(3) receptor antagonists.
    Sander K, von Coburg Y, Camelin JC, Ligneau X, Rau O, Schubert-Zsilavecz M, Schwartz JC, Stark H.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1581-4. PubMed ID: 20138762
    [Abstract] [Full Text] [Related]

  • 16. Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition.
    Berglund S, Egner BJ, Gradén H, Gradén J, Morgan DG, Inghardt T, Giordanetto F.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4268-73. PubMed ID: 19500979
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships of new 1-substitutedmethyl-4-[5-(N-methyl-N-propylamino)pentyloxy]piperidines and selected 1-[(N-substituted-N-methyl)-3-propyloxy]-5-(N-methy-l-N-propyl)-pentanediamines as H3 -antagonists.
    Masłowska-Lipowicz I, Walczyński K.
    Chem Biol Drug Des; 2014 Jan 01; 83(1):106-18. PubMed ID: 23957330
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.
    Jitsuoka M, Tsukahara D, Ito S, Tanaka T, Takenaga N, Tokita S, Sato N.
    Bioorg Med Chem Lett; 2008 Sep 15; 18(18):5101-6. PubMed ID: 18768318
    [Abstract] [Full Text] [Related]

  • 19. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD, Sher R, Berlin M, Shih NY, Aslanian R, Schwerdt JH, McCormick KD, Piwinski JJ, West RE, Anthes JC, Williams SM, Wu RL, She HS, Rivelli MA, Mutter JC, Corboz MR, Hey JA, Favreau L.
    Bioorg Med Chem Lett; 2006 Jan 15; 16(2):395-9. PubMed ID: 16246552
    [Abstract] [Full Text] [Related]

  • 20. Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness.
    Wingen K, Schwed JS, Isensee K, Weizel L, Zivković A, Odadzic D, Stark H.
    Bioorg Med Chem Lett; 2014 May 15; 24(10):2236-9. PubMed ID: 24745967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.